Hypertension Detection and Follow-up Program

Presentation of 5-year Mortality Results
The National Heart, Lung, and Blood Institute (NHLBI) has several multi-year clinical trials under way, and these findings are those reported at the conclusion of the Hypertension Detection and Follow-up Program (HDFP) at a press briefing on November 27, 1979, at the National Institutes of Health in Bethesda, Maryland.

Statements and comments made within this document are based on the November 27th presentations by the following:

Robert I. Levy, M.D.
Director
National Heart, Lung, and Blood Institute

Gerald H. Payne, M.D.
Scientific Project Officer, HDFP
National Heart, Lung, and Blood Institute

Herbert Langford, M.D.*
Chairman
HDFP Steering Committee

Jeremiah Stamler, M.D.*
Vice Chairman
HDFP Steering Committee

October 1980
*Further identified on page 9
Hypertension Detection and Follow-up Program

Presentation of 5-year Mortality Results

In 1972, there were many unanswered questions regarding the treatment of high blood pressure. Although, the Veterans Administration (VA) trials demonstrated that drug therapy was effective in preventing stroke, renal failure and heart failure in males with moderate to severe hypertension, we did not know the extent to which the VA findings could generally be applied to the community at large or to women, minorities, the young or to individuals with "mild" hypertension - those with a diastolic blood pressure between 90 and 105.

At that time the NHLBI launched two major efforts:

The first -- the National High Blood Pressure Education Program -- to inform the public and health care professional about the facts and opportunities on hand about high blood pressure so as to stimulate more awareness and aggressive treatment of the disease.

The second -- the Hypertension Detection and Follow-up Program -- to gain additional facts and to resolve unsettled issues regarding the treatment of high blood pressure.

Magnitude and Impact of Hypertension

- 35 million Americans have definite hypertension
- An additional 25 million have so-called borderline hypertension

Hypertension:

- Is the most important factor contributing to 500,000 cases of stroke each year resulting in 175,000 deaths
- Is a very significant factor in the 1,250,000 heart attacks that occur each year
- Costs this Nation more than $8 billion annually

Research Advances

Prior to 1972

The National High Blood Pressure Education Program

The Hypertension Detection and Follow-up Program

NHBPEP

HDFP
Hypertension Detection and Follow-up Program

There have been encouraging indicators of progress associated with the National High Blood Pressure Education Program, a program coordinated by the National Heart, Lung, and Blood Institute but involving numerous Federal, private and voluntary agencies and organizations. The public is now more understanding of high blood pressure and its implications. Patient visits for the detection and treatment of high blood pressure have steadily climbed. There is a growing number of health professionals who have accepted, and continue to accept, the program's recommended approach for managing the disease.

Most significantly, and this is the final bottom line in any disease prevention program, progress in controlling high blood pressure is temporarily associated with the dramatic decline in death rates from cardiovascular disease, particularly in the case of stroke.

In the 1940's and 1950's, stroke deaths were falling at about one and one-half percent each year. Since the beginning of the National High Blood Pressure Education Program in 1972, stroke death rates have plummeted over 5 percent each year. From 1972 through 1978, we have witnessed a 31.7 percent decrease in stroke deaths in this country.

Cerebrovascular Diseases: Crude and Age-Adjusted* Death Rates, United States, 1962-1978

![Cerebrovascular Diseases Graph]

*Age-Adjusted to U.S. Population, 1940

Source: National Center for Health Statistics

Trends in Cardiovascular Disease and Noncardiovascular Disease: Decline by Age-Adjusted Death Rates, 1968-1978

![Trends in Cardiovascular Disease Graph]
Hypertension Detection and Follow-up Program

The emphasis of the NHLBI with the National High Blood Pressure Education Program has shifted with time from one of awareness and detection to the more difficult area of adherence to treatment. The major theme has become making physicians and the public alike aware of the necessity and value of staying on a treatment regimen in order to avoid symptomatic cardiovascular disease and premature death.

As the national education program was implemented, the NHLBI also carried out the HDFP, a multicenter clinical trial designed to find answers to questions which are as pertinent today as they were in 1972:

- Is a systematic aggressive approach to hypertension effective in reducing mortality for hypertensive adults in the community setting?
- Can a substantial proportion of all hypertensives detected in the general population be brought under medical management aimed at reducing blood pressure to normal levels, and can they be kept under management?
- Do the benefits of hypertension treatment exceed possible toxicity, especially in the case of patients with so-called “mild” hypertension?
- Is antihypertensive therapy effective in young adults, women, and equally effective in blacks and whites?
- Can mortality from coronary heart disease (from heart attack) be decreased by antihypertensive therapy?
Hypertension Detection and Follow-up Program

Purpose and Basic Design

The primary purpose of the Hypertension Detection and Follow-up Program was to determine whether a systematic approach of antihypertensive therapy (Stepped Care) compared with community care is effective in reducing risk of 5-year mortality for adults with elevated diastolic blood pressure in the community.

This effort embraced a wide spectrum of adults from 14 communities:

Study Population: 10,940 persons, age 30-69 and with elevated diastolic blood pressure
Duration of Follow-up: 5 years
Treatment Groups: Stepped Care: 5,485 participants treated in HDFP centers
Referred Care: 5,455 participants referred to private physicians or other community sources of care
Primary Endpoint: All-cause mortality

Stepped Care

The stepped care group was offered free antihypertensive therapy in special centers. Therapy was increased stepwise to achieve and maintain reduction of blood pressure to or below set goals. Emphasis was on clinic attendance and adherence to medication schedules. Economic barriers to adherence were removed as much as possible. Waiting times were minimized by efficient operation and use of allied health personnel. Appointments were made at convenient hours. A program physician was on call at all times to deal with problems related to hypertension.

Goal Diastolic Blood Pressure

The goal diastolic blood pressure (DBP) was 90 mm Hg for those entering with DBP of 100 mm Hg or greater and for those receiving antihypertensive medication at entry. The goal DBP was a 10 mm Hg decrease for those entering the program with DBP of 90-99 mm Hg.

Stepped Care Drug Regimens

Step 1: The diuretic, chlorthalidone, is the primary agent.
- Triamterene or spironolactone can be used as a supplement.

Step 2: Chlorthalidone plus reserpine.
- Methyldopa may be substituted for reserpine if the latter is contraindicated.

Step 3: Chlorthalidone plus reserpine plus hydralazine.
- Methyldopa may be substituted for reserpine.

Step 4: Chlorthalidone ± reserpine, ± hydralazine plus guanethidine.

Step 5: Individualized therapy.
- Only FDA approved antihypertensive agents can be prescribed in the program centers. Other antihypertensive drugs approved by FDA during the trial were made available for Step 5 use.

Step 0: If goal blood pressure was achieved at the first treatment visit without antihypertensive medication, no treatment was prescribed at that time.
Hypertension Detection and Follow-up Program

Mortality - All Causes

5-Year Mortality Rates (%) From All Causes for Stepped Care (SC) and Referred Care (RC) Participants

![Graph showing mortality rates for SC and RC participants.]

Mortality - All Causes by DBP

5-Year Mortality Rates (%) From All Causes for Stepped Care (SC) and Referred Care (RC) Participants By Diastolic Blood Pressure (DBP) Stratum at Entry

![Graph showing mortality rates by DBP stratum.]

HDFP Entry Diastolic Blood Pressure (DBP) Strata

<table>
<thead>
<tr>
<th>Stratum I (DBP 90-104 mmHg)</th>
<th>N</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stratum II (DBP 105-114 mmHg)</td>
<td>2,052</td>
<td>18.8</td>
</tr>
<tr>
<td>Stratum III (DBP 115 mmHg and higher)</td>
<td>1,063</td>
<td>9.7</td>
</tr>
</tbody>
</table>

Total 10,940 100.0
Hypertension Detection and Follow-up Program

Mortality - All Causes by Race
5-Year Mortality Rates (%) From All Causes for Stepped Care (SC) and Referred Care (RC) Participants By Race

<table>
<thead>
<tr>
<th>Percent</th>
<th>SC</th>
<th>RC</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.8</td>
<td>7.6</td>
<td>6.0</td>
</tr>
<tr>
<td>22.4%</td>
<td>10.0%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deaths</th>
<th>SC</th>
<th>RC</th>
</tr>
</thead>
<tbody>
<tr>
<td>238</td>
<td>182</td>
<td>167</td>
</tr>
</tbody>
</table>

N=2,438 N=2,408 N=3,017 N=3,077

Mortality - All Causes by Age
5-Year Mortality Rates (%) From All Causes for Stepped Care (SC) and Referred Care (RC) By Age at Entry

<table>
<thead>
<tr>
<th>Percent</th>
<th>SC</th>
<th>RC</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.5</td>
<td>3.3</td>
<td>6.2</td>
</tr>
<tr>
<td>22.4%</td>
<td>10.0%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deaths</th>
<th>SC</th>
<th>RC</th>
</tr>
</thead>
<tbody>
<tr>
<td>82</td>
<td>159</td>
<td>153</td>
</tr>
</tbody>
</table>

N=2,374 N=2,429 N=1,909 N=1,852 N=1,172 N=1,204

Mortality - All Causes by Sex
5-Year Mortality Rates (%) From All Causes for Stepped Care (SC) and Referred Care (RC) Participants By Sex

<table>
<thead>
<tr>
<th>Percent</th>
<th>SC</th>
<th>RC</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.1</td>
<td>7.5</td>
<td>8.1</td>
</tr>
<tr>
<td>17.6%</td>
<td>16.4%</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Deaths</th>
<th>SC</th>
<th>RC</th>
</tr>
</thead>
<tbody>
<tr>
<td>266</td>
<td>221</td>
<td>153</td>
</tr>
</tbody>
</table>

N=2,945 N=2,956 N=2,510 N=2,529

Demographic Characteristics
Demographic Characteristics of Stepped Care and Referred Care Participants

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Stepped Care</th>
<th>Referred Care</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number</td>
<td>5,485</td>
<td>5,455</td>
</tr>
<tr>
<td>Average Age (years)</td>
<td>50.8</td>
<td>50.8</td>
</tr>
<tr>
<td>% Blacks</td>
<td>43.9</td>
<td>44.7</td>
</tr>
<tr>
<td>% Whites</td>
<td>56.1</td>
<td>55.3</td>
</tr>
<tr>
<td>% Men</td>
<td>53.9</td>
<td>54.0</td>
</tr>
<tr>
<td>% Women</td>
<td>46.1</td>
<td>46.0</td>
</tr>
</tbody>
</table>

1Non-black minorities represent less than 1% of participants and are included in the category - "Whites."
The HDFP has been a successful study. As great as the national death rate declines have been, the HDFP has achieved an even better outcome. Looking at the so-called “control group” for this trial, our investigators agree that if we had not had a successful national high blood pressure education effort, the findings of the HDFP would be even more dramatic.

People with high blood pressure, who undergo systematic care will live considerably longer than those who receive no care or routine care. If everybody who is now under treatment for high blood pressure were given this systematic care, it might be possible to reduce premature death among hypertensives by 17 percent.

Looking at it another way, tens of thousands of Americans with high blood pressure are now probably dying at an earlier age than they should.

Of the approximately 25 million Americans with so-called “mild” hypertension, millions are not being treated because they or their doctors feel that there is little benefit in treating hypertension if it is in the mild range. Until now, there wasn’t clear scientific proof of the benefits of treating this group of patients.

This study clearly demonstrates that the systematic, effective treatment of mild hypertension may reduce premature deaths by 20 percent.

It is important to remember that the control group in this study was not a placebo group. This was not a case of comparing good care with no care. It was a comparison of aggressive versus the typical care one would find in our communities. And the fact that the care routinely given in communities today for high blood pressure has improved considerably over recent years, just adds to the significance of this study and to the basic finding that systematic care of high blood pressure saves lives.

To the millions of Americans who have high blood pressure, this study says: Get on treatment and stay on treatment. It will mean a much longer life... more years to spend with your loved ones.

To the physicians with high blood pressure patients, it says: Take the necessary steps to make sure your
patients follow your instructions and stay on their treatment. It also says that if you have patients with mild hypertension, you can now offer them treatment which may add years to their lives.

The multiyear Hypertension Detection and Follow-up Program will have a final cost of between 60 and 70 million dollars. But, if we apply the lessons learned as a result of HDFP, we will see a return well into the billions of dollars as the number of premature deaths decrease among the millions of hypertensives in this country.

In the 1980 Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure the following guidelines are presented:

“Dietary management is a reasonable initial approach in young patients with uncomplicated mild hypertension and no additional cardiovascular risk factors. To be successful in the long run, extended nutritional counseling may be necessary. If nondrug treatment reduces blood pressure and maintains it at normal levels, it may be considered definitive therapy. If diet proves ineffective in normalizing blood pressure after an adequate trial, drug therapy should be considered in addition.”

“Factors that support the decision to initiate drug treatment in patients with mild hypertension include: presence of target organ damage; smoking; family history of premature cardiovascular complications; elevated systolic blood pressure; diabetes; and elevated cholesterol level.”
Hypertension Detection and Follow-up Program

Steering Committee

Principal Investigators - Clinical Centers

Herbert Langford, M.D. (Chairman)
Chief, Endocrinology and Hypertension Division
University of Mississippi Medical Center
Jackson, Mississippi
(601) 968-5629

Jeremiah Stamler, M.D. (Vice Chairman)
Professor and Chairman, Department of
Community Health and Preventive Medicine
Northwestern University Medical School
Chicago, Illinois
(312) 649-7914

Rauen Reerman, M.D.
Clinical Studies Center
Mount Sinai Hospital
Minneapolis, Minnesota
(612) 871-3700 x575

George Entwistle, M.D.
Department of Social and Preventive Medicine
University of Maryland
Baltimore, Maryland
(301) 528-5077

Morton Maxwell, M.D.
Director, Hypertension Service
Cedars-Sinai Medical Center
Los Angeles, California
(213) 855-4671

M. Donald Blaufox, M.D., Ph.D.
Baum Reitter Kidney Center
Albert Einstein College of Medicine
Bronx, New York
(212) 931-5770

Curtis G. Hames, M.D.
Co-county Health Officer
Evans County Health Department
Claxton, Georgia
(912) 739-1231

Albert Oberman, M.D.
Director, Division of Preventive Medicine
University of Alabama
Birmingham, Alabama
(205) 934-4140

Nemat O. Borhani, M.D.
Professor and Chairman
Department of Community Health
UCD School of Medicine
Davis, California
(916) 752-2793

John W. Jones, M.D.
Professor of Medicine
Michigan State University
Lansing, Michigan
(517) 487-3677

Lawrence M. Slotkoff, M.D., Ph.D.
Professor of Medicine
Georgetown University
Washington, D.C.
(202) 626-5604

C. Hilmon Castle, M.D.
Professor and Chairman
Department of Family and Community Medicine
University of Utah College of Medicine
Salt Lake City, Utah
(801) 581-8119

Edward H. Kass, M.D., Ph.D.
Director, Channing Laboratory
Harvard Medical School
Boston, Massachusetts
(617) 732-2270

Elbert P. Tuttle, Jr., M.D.
Professor of Medicine
Emory University
Atlanta, Georgia
(404) 659-1847

Coordinating Center
C. Morton Hawkins, Sc.D.
Professor of Biometry
University of Texas
School of Public Health
Houston, Texas
(713) 792-4480

Central Laboratory
Agostino Molteni, M.D., Ph.D.
Professor of Pathology
Northwestern University
Chicago, Illinois
(312) 649-2417

ECG Laboratory
Ronald J. Prineas, M.B., Ph.D.
Associate Professor
University of Minnesota
School of Public Health
Minneapolis, Minnesota
(612) 373-3586

NHLBI, DHVD Staff Members:

Gerald H. Payne, M.D.
Scientific Project Officer, HDFP
(301) 496-2465

Wallace R. Williams, Ph.D.
Deputy Project Officer, HDFP
(301) 496-2465

Thomas P. Blaszkowski, Ph.D.
Office of Associate Director
Clinical Applications and Prevention Program
(301) 496-1844

James H. Ware, Ph.D.*
Acting Chief, Biometrics Research Branch

*Now at Harvard School of Public Health, Cambridge, Massachusetts.
Hypertension Detection and Follow-up Program

Policy Advisory Board

Alvin P. Shapiro, M.D. (Chairman)
Professor of Medicine
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania

Glen E. Bartsch, Ph.D.
Biometry Division
School of Public Health
University of Minnesota
Minneapolis, Minnesota

Kenneth G. Bergs, M.D.
Consultant in Medicine
Mayo Clinic
Rochester, Minnesota

Edward S. Cooper, M.D.
Professor of Medicine
University of Pennsylvania
Medical Group
Philadelphia, Pennsylvania

Edward D. Frohlich, M.D.
Vice President
Research and Education
Alton Ochsner Medical Foundation
New Orleans, Louisiana

Richard H. Gaddadan, Ph.D.
Professor of Biochemistry and Clinical Pathology
Medical University of South Carolina
Charleston, South Carolina

David L. Sackett, M.D.
Department of Clinical Epidemiology and Biostatistics
McMaster University Medical Center
Hamilton 16, Ontario, Canada

Joseph Wilber, M.D.
Director, Adult Health Section
Georgia Department of Public Health
Atlanta, Georgia

NHLBI, DHVD, Staff Members:

William T. Friedewald, M.D.
Associate Director
Clinical Applications and Prevention (CAP)

William J. Zukel, M.D.
Associate Director
Program Coordination and Planning (PCP)

Toxicity and Endpoints Evaluation Committee

Outside Members

W. McFate Smith, M.D., M.P.H. (Chairman)
University of California-USPHS Hospital
San Francisco, California

Max Halperin, Ph.D.
School of Public Health
University of North Carolina
Chapel Hill, North Carolina

Louis S. Monk, Ph.D.
818 Malibu Drive
Silver Spring, Maryland

Walter M. Kirkendall, M.D.
Professor of Medicine
University of Texas Medical School
Houston, Texas

Richard D. Remington, Ph.D.
Dean, School of Public Health
University of Michigan
Ann Arbor, Michigan

Curtis L. Meinert, Ph.D.
School of Hygiene and Public Health
Johns Hopkins University
Baltimore, Maryland

Alvin P. Shapiro, M.D.
Professor of Medicine
University of Pittsburgh
School of Medicine
Pittsburgh, Pennsylvania

Steering Committee Members

C. Morton Hawkins, Sc.D.
Director
HDFP Coordinating Center

Harold W. Schnaper, M.D.
Co-Investigator
Birmingham Center

Edward H. Kass, M.D., Ph.D.
Principal Investigator
Boston Center

Jeremiah Stamler, M.D.
Principal Investigator
Chicago Center

Herbert Langford, M.D.
Principal Investigator
Jackson Center

DHVD, NHLBI Staff Members

Thomas P. Blaszkowski, Ph.D.
Office of Associate Director, CAP

Gerald H. Payne, M.D.
Scientific Project Officer, HDFP

Wallace R. Williams, Ph.D.
Deputy Project Officer, HDFP

William J. Zukel, M.D.
Associate Director, PCP